ZURICH (Reuters) - Lonza said on Tuesday the first patient has been treated with a cell therapy made in its "Cocoon" platform, which the Swiss contract drug maker hopes catches on at medical centers ...

Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform. On Aug. 12, 2021, Lonza and Sheba ...

Lonza’s CocoonTM manufacturing platform will be used by Israel’s largest hospital, Sheba Medical Center at Tel Hashomer, to develop point-of-care cell-therapy manufacturing. Cocoon has been designed ...

IsoLight ® automated proteomics platform will be used for functional quality analytics for products produced on Lonza’s Cocoon ® automated cell manufacturing system. IsoPlexis, which markets ...

Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, ...

- Goal to rapidly develop several T-cell therapies on the Cocoon ® Platform for clinical point-of-care manufacturing - Aims to reduce vein-to-vein time for patients to 5-7 days LEIDEN, Netherlands, ...

Lonza plans to ensure consistent product quality by incorporating Agilent’s analytics technology into its Cocoon platform. Lonza and Agilent announced a strategic collaboration to incorporate new ...

BASEL, Switzerland & MONTRÉAL & AUSTIN, Texas--(BUSINESS WIRE)--Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell ...